Healthcare Mar 09, 2022 10:52 AM (GMT+8) · EqualOcean
Recently, Nanjing Kati Medical Technology Co., Ltd., a domestic cutting-edge enterprise of car-t cell therapy for solid tumors, completed a round of a + financing with a total amount of more than 70 million yuan. This round of financing is jointly completed by Nanjing Chengyi investment, Qiandao group, Suzhou Guanya investment and Haihui investment. This round of financing will be mainly used to promote the application of the leading product ind of Kati medicine. Founded in 2017 and headquartered in Nanjing Biological Medicine Valley in Nanjing National Jiangbei new area, Kati medicine is a key enterprise in the field of gene and life health and a national high-tech innovation enterprise in Jiangbei new area. Kati medicine focuses on the development of new drugs for car-t cells in solid tumors.

This text is a result of machine translation.